Bristol-Myers Squibb Company (BRM.DE)

XETRA - XETRA Delayed price. Currency in EUR

Add to watchlist

46.34

+1.42

(+3.17%)

At close: 05:35PM CEST

Loading interactive chart…

Business Wire
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
PRINCETON, N.J., September 27, 2024--U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
Barrons.com
These Stocks Moved the Most Today: Bristol Myers, Costco, EchoStar, Cassava, DJT, Wynn, HP Inc., Acadia Healthcare, and More
Bristol Myers trades higher after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter revenue at Costco misses analysts’ estimates, and EchoStar rises on reports its Dish subsidiary is in merger talks with DirecTV.
Business Wire
Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting
PRINCETON, N.J., September 27, 2024--BMS Presents New Data from Two Trials Demonstrating Sotyktu Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting